133 related articles for article (PubMed ID: 1663042)
1. N omega-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast.
Dundore RL; Pratt PF; O'Connor B; Buchholz RA; Pagani ED
Eur J Pharmacol; 1991 Jul; 200(1):83-7. PubMed ID: 1663042
[TBL] [Abstract][Full Text] [Related]
2. Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats.
Dundore RL; Clas DM; Wheeler LT; Habeeb PG; Bode DC; Buchholz RA; Silver PJ; Pagani ED
Eur J Pharmacol; 1993 Nov; 249(3):293-7. PubMed ID: 8287916
[TBL] [Abstract][Full Text] [Related]
3. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo.
De Garavilla L; Pagani ED; Buchholz RA; Dundore R; Bode DC; Volberg ML; Jackson KN; Pratt P; Silver PJ
Eur J Pharmacol; 1996 Oct; 313(1-2):89-96. PubMed ID: 8905333
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
Harris AL; Lemp BM; Bentley RG; Perrone MH; Hamel LT; Silver PJ
J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Merkel LA; Rivera LM; Perrone MH; Lappe RW
Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
[TBL] [Abstract][Full Text] [Related]
6. Lack of cross-tolerance between nitroglycerin and endothelium-derived relaxing factor-mediated vasoactive agents in spontaneously hypertensive rats.
De Garavilla L; Volberg ML; Pratt PF; Silver PJ; Buchholz RA
Eur J Pharmacol; 1993 Mar; 234(1):77-82. PubMed ID: 8386094
[TBL] [Abstract][Full Text] [Related]
7. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
Silver PJ; Dundore RL; Bode DC; de Garavilla L; Buchholz RA; van Aller G; Hamel LT; Bacon E; Singh B; Lesher GY
J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
[TBL] [Abstract][Full Text] [Related]
8. Possible mechanisms of age-associated reduction of vascular relaxation caused by atrial natriuretic peptide.
Moritoki H; Yoshikawa T; Hisayama T; Takeuchi S
Eur J Pharmacol; 1992 Jan; 210(1):61-8. PubMed ID: 1350988
[TBL] [Abstract][Full Text] [Related]
9. Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3',5'-monophosphate-selective phosphodiesterase inhibitor.
McMahon EG; Palomo MA; Mehta P; Olins GM
J Pharmacol Exp Ther; 1989 Dec; 251(3):1000-5. PubMed ID: 2557409
[TBL] [Abstract][Full Text] [Related]
10. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed.
McMahon TJ; Ignarro LJ; Kadowitz PJ
J Appl Physiol (1985); 1993 Apr; 74(4):1704-11. PubMed ID: 8390441
[TBL] [Abstract][Full Text] [Related]
11. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts.
Weiss HR; Rodriguez E; Tse J; Scholz PM
Clin Exp Pharmacol Physiol; 1994 Aug; 21(8):607-14. PubMed ID: 7813120
[TBL] [Abstract][Full Text] [Related]
12. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs.
Braner DA; Fineman JR; Chang R; Soifer SJ
Am J Physiol; 1993 Jan; 264(1 Pt 2):H252-8. PubMed ID: 8381611
[TBL] [Abstract][Full Text] [Related]
13. Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast.
Silver PJ; Pagani ED; de Garavilla L; Van Aller GS; Volberg ML; Pratt PF; Buchholz RA
Eur J Pharmacol; 1991 Jun; 199(1):141-2. PubMed ID: 1654265
[No Abstract] [Full Text] [Related]
14. Sodium nitroprusside potentiates the depressor response to the phosphodiesterase inhibitor zaprinast in rats.
Dundore RL; Pratt PF; Hallenbeck WD; Wassey ML; Silver PJ; Buchholz RA
Eur J Pharmacol; 1990 Aug; 185(1):91-7. PubMed ID: 1977600
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.
Trapani AJ; Smits GJ; McGraw DE; McMahon EG; Blaine EH
J Pharmacol Exp Ther; 1991 Jul; 258(1):269-74. PubMed ID: 1649294
[TBL] [Abstract][Full Text] [Related]
16. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast.
Pagani ED; VanAller GS; O'Connor B; Silver PJ
Eur J Pharmacol; 1993 Oct; 243(2):141-7. PubMed ID: 8276063
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of zaprinast on methacholine-induced contraction and inositol 1,4,5-trisphosphate accumulation in bovine tracheal smooth muscle.
Chilvers ER; Giembycz MA; Challiss RA; Barnes BJ; Nahorski SR
Br J Pharmacol; 1991 May; 103(1):1119-25. PubMed ID: 1652339
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells.
Papapetropoulos A; Go CY; Murad F; Catravas JD
Br J Pharmacol; 1996 Jan; 117(1):147-55. PubMed ID: 8825356
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
Anderson IK; Drew GM
Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286
[TBL] [Abstract][Full Text] [Related]
20. L-Arginine, a precursor of EDRF in vitro, produces pulmonary vasodilation in lambs.
Fineman JR; Chang R; Soifer SJ
Am J Physiol; 1991 Nov; 261(5 Pt 2):H1563-9. PubMed ID: 1659228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
